Abstract:Abstract Ewing sarcoma (ES) is a rare, highly aggressive cancer of the bone and soft tissues that mainly affects children and young adults. The most common driver of ES is a chromosomal translocation between the EWSR1 gene and an ETS family member, most frequently FLI1. This leads to the expression of an aberrant transcription factor called EWS::FLI1 (EF1) that acts as an epigenetic reprogrammer and transcriptional modulator. Previous studies on ES cell lines showed that EF1 levels are dynamic where cells with high EF1 levels are more proliferative, while cells with low EF1 levels have a strong propensity to migrate and metastasize. However, there is no direct evidence of EF1 fluctuations on a functional protein level. Moreover, the upstream modulators or pathways regulating EF1 thresholds and their corresponding consequences on ES tumorigenesis are poorly understood. Thus, we aimed to develop an ES screening model to identify EF1 regulators by performing a high-throughput drug screen and a genome-wide CRISPR/Cas9 knockout screen. This model was established by endogenously tagging EF1 of ES cell lines (A673, TC71) with a fluorescent tag (mNeonGreen) together with a degradation tag (dTAG) using CRISPR/Cas9 knock-in. The fluorescent tag serves for the readout of altered EF1 expression on multiple levels (transcriptional, post-transcriptional, translational, post-translational, and epigenetic). At the same time, dTAG allows mimicking rapid and acute EF1 perturbation-specific cell states upon treatment with a VHL-recruiting ligand (dTAGv-1). The successful knock-in clones with edited EF1 were extensively characterized compared to the wildtype EF1 cells with respect to cellular morphology, subcellular EF1 localization, stability, and target gene expression to rule out a loss of EF1 function due to the addition of the tags. The results from the high throughput drug screen (2.5K custom compound library) resulted in a candidate list of EF1 up- and down-regulators involving genes of various cancer signaling pathways (PI3K/AKT/mTOR, IGF-1, ALK pathway), cell cycle regulators (CDKs, AURKA, PLK1) and epigenetic regulators (HDACs, BETs). In the next steps, the drug targets will be compared to the gene hits from the CRISPR screen in an unbiased manner to identify novel EF1-regulatory pathways. Moreover, the functional consequences of treatment with EF1-modulatory compounds on ES tumorigenesis will be studied. Together, our study will promote a better understanding of factors affecting EF1 thresholds and ES plasticity and help identify potential therapeutic targets for ES. Citation Format: Veveeyan Suresh, Valerie Fock, Beat Schäfer, Heinrich Kovar. A novel screening model to identify EWS::FLI1 regulators and their consequences on Ewing sarcoma plasticity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1467.

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing

The eukaryotic translation initiation factor eIF4E reprograms alternative splicing

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

Functional and therapeutic significance of ESR1 gene fusions in breast cancer

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation

Role of epithelial splicing regulatory protein 1 in cancer progression

Abstract 3033: Oncogenic ETS transcription factors avoid repression by EZH2 and FOXO1 in prostate cancer and Ewing sarcoma

Insights into Molecular Diversity within the FUS/EWS/TAF15 Protein Family: Unraveling Phase Separation of the N-Terminal Low-Complexity Domain from RNA-Binding Protein EWS

ETS1, a target gene of the EWSR1::FLI1 fusion oncoprotein, regulates the expression of the focal adhesion protein TENSIN3

ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation

Abstract 1467: A novel screening model to identify EWS::FLI1 regulators and their consequences on Ewing sarcoma plasticity

Significance of Alternative Splicing in Cancer Cells.

Endogenous EWSR1-FLI1 degron alleles enable control of fusion oncoprotein expression in tumor cell lines and xenografts

EWS-FLI1 employs an E2F switch to drive target gene expression

Reconstruction of Ewing Sarcoma Developmental Context from Mass-Scale Transcriptomics Reveals Characteristics of EWSR1-FLI1 Permissibility

Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9

The Role of Alternative Splicing Factors hnRNP G and Fox-2 in the Progression and Prognosis of Esophageal Cancer

Functional Requirement of Alternative Splicing in Epithelial-Mesenchymal Transition of Pancreatic Circulating Tumor

EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma

Alternative splicing in EMT and TGF-β signaling during cancer progression